elsilimomab

Modify Date: 2024-01-20 12:48:53

elsilimomab structure	Common Name	elsilimomab
	CAS Number	468715-71-1	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of elsilimomab

Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)[1][2][3].

Name	elsilimomab

Description	Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
Target	IL-6:1.4 nM (IC50)
In Vitro	Elsilimomab 特异性抑制 IL-6，但不抑制 LIF (白血病抑制因子)诱导的细胞生长[2]。 Elsilimomab (20 μg/mL) 可中和人 IL-6[2]。 Cell Viability Assay[2] Cell Line: Murine B9 cells Concentration: 20 μg/mL Incubation Time: 3 days Result: B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.
References	[1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265. [2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390. [3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.

No Any Chemical & Physical Properties

elsilimomab

Use of elsilimomab

Names

elsilimomab Biological Activity

Chemical & Physical Properties